AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06155903 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral nerve blocks
Description: In this group, four nerve blocks will be associated to ensure adequate anesthesia and analgesia during surgery.~Sciatic nerve blocks with para sacral approach will be performed with a needle connected to an electrical nerve stimulation. The needle will be advanced until contraction of the related muscles. Next, an anesthetic solution of Ropivacaine 0.375% (dose 37.5 mg) plus Mepivacaine 1% (dose 100 mg) and Dexamethasone 4mg, total volume 21 ml, will be injected.~Lateral femoral cutaneous, femoral and obturator nerve blocks, femoral will be performed with the ultrasound technique. After identifying the nerves, a needle will be inserted with an in plane approach and will be injected.~The anesthesia mixture will consist for all of :Ropivacaine 0.375% plus Mepivacaine 1% plus dexamethasone 4 mg.~The volumes of the 3 anesthesia mixtures will be respectively: 1ml, 15ml,5ml.
Study NCT06155903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anesthesiological mixtures (Spinal anesthesia)
Description: The anesthesia mixtures will be injected into the subarachnoid space for spinal anesthesia. It will consist of the following local anesthetics and adjuvants: Hypobaric Bupivacaine 0.5% 7.5 mg and Sufentanil 5 µg.
Study NCT06155903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anesthesiological mixtures (Peripheral nerve block)
Description: The anesthesia mixtures will be injected into selected peripheral nerves . It will consist of the following local anesthetics and adjuvants: Ropivacaine 0.375% plus Mepivacaine 1% and Dexamethasone 4 mg.
Study NCT06548490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Pen Injector
Description: Semaglutide will be provided using an injection pen
Study NCT06548490 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be a dry needle stick; no substances will be injected
Study NCT04814082 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MicroPort Evolution Medial-Pivot Knee System (Cruciate-substituting)
Description: Medial Pivot Knee System
Study NCT04814082 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stryker Triathlon Tritanium Knee System (Condylar Stabilizing)
Description: Single Radius Design Total Knee System
Study NCT05538663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravesical once a week for 6 consecutive weeks followed by monthly instillations during maintenance for 2 years
Study NCT05538663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Intravesical once a week for 6 consecutive weeks followed by monthly instillations during maintenance for 2 years
Study NCT05538663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette Guerin
Description: intravesical once a week for 6 consecutive weeks during induction followed by weekly instillations for 3 consecutive weeks at months 3, 6, 12, 18, 24, 30, and 36 months
Study NCT05228197 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biopsy & Imaging
Description: H\&E stained prostate biopsy slides from standard of care treatment
Study NCT05223816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection [Opdivo]
Description: immunotherapy treatment
Study NCT06043648 — intervention group
Intervention type: DEVICE
Intervention: Endotracheal tube cuff pressure monitoring
Description: The endotracheal tube cuff pressure was continuously monitored using a transducer from a standard invasive pressure monitoring device that is routinely used to measure arterial or central venous pressure.
Study NCT06414603 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: The Prospera™ Test
Description: The Prospera™ test is a non-invasive test intended to detect and quantify the fraction of donor-derived cell-free DNA (dd-cfDNA) to supplement management and surveillance of allograft rejection in patients who have undergone organ transplantation. It employs Next Generation Sequencing (NGS), which is performed on cell-free DNA (cfDNA) that is extracted from the patient's plasma to discriminate between the patient's DNA and the solid organ-allograft DNA.~In study 23-069-TRP, the Prospera test is indicated for heart allograft rejection surveillance in lieu of surveillance endomyocardial biopsy. Prospera results should be considered together with clinical evaluations and other diagnostic testing or imaging results. Prospera will be run as a centralized laboratory developed test that is developed and validated under Design Controls. The test will be run within Natera's CLIA-certified and CAP-accredited laboratory.
Study NCT06302049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: esomeprazole 20 mg once daily
Study NCT06302049 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily
Study NCT06467747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Music group: wear earphones to listen to music and receive standardized anesthesia protocol
Study NCT06467747 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mute
Description: Mute group: wear earphones without music and receive standardized anesthesia protocol
Study NCT06439277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC
Study NCT06439277 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT06538259 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)-anodal group
Description: 2mA/20mins/session; 2sessions/day,5days
Study NCT06538259 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)-sham group
Description: 0mA/20mins/session; 2sessions/day,5days
Study NCT06500429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NG101
Description: Drug: Including placebo
Study NCT06500429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Including placebo
Study NCT06500429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Injectable Product
Description: Semaglutide 0.5 or 1 mg
Study NCT06500429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Semaglutide Injectable Product
Description: Semaglutide 0.5 or 1 mg
Study NCT04844606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered SC
Study NCT04844606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered IV
Study NCT06477705 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FAM
Description: Participants will perform a recreational Football Training session for 60 minutes. The training will include the warm-up, soccer technical exercises and a small-side game
Study NCT05003869 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scar tissue is removed
Description: The patients were divided into two groups according to whether the scar tissue was removed during TCRA operation: study group: resection of uterine scar tissue during TCRA operation;In the control group, the scar tissue covering the anterior, posterior and lateral walls of the uterine cavity was ploughed longitudinally into several narrow strips using needle-like electrodes, and the scar tissue was not excised.
Study NCT05404711 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CGM
Description: Participants will wear blinded Dexcom G6 Pro continuously for 10 days in their home environment. Two challenges will be completed at home: 1) glucose, using 1.75 g/kg (max 75g) glucose beverage provided by study team, and 2) mixed food, containing 50g carb as well as protein and fat content of participant's choice.
Study NCT06608407 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP group
Description: After the completion of hysteroscopic adhesiolysis, recruited participants will be randomized to one of the two treatment groups by computer-generated numbers: Immediately administer uterine perfusion with PRP after surgery, and administered PRP perfusion during hysteroscopy at 4 and 8 weeks after hysteroscopic adhesiolysis, A second-look hysteroscopy and ultrasound assessment of the endometrium will be carried out 4 weeks after the surgery, and again at 8 weeks after the surgery. Control group without PRP treatment.
Study NCT06609408 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nature and Game Based Activities
Description: Individuals in experimental group will participate nature and game activities such as terrarium making, planting flowers, making puzzles in intervention.
Study NCT06611566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR-guided aerobic exercise
Description: The intervention was 5 minutes of VR-guided aerobic exercise
Study NCT06611566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR-guided mindfulness exercise
Description: The intervention was 5 minutes of VR-guided mindfulness exercise
Study NCT06611566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TV-guided aerobic exercises
Description: The intervention was 5 minutes of TV-guided aerobic exercises
Study NCT06611566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TV-guided mindfulness exercises
Description: The intervention was 5 minutes of VR-guided mindfulness exercises
Study NCT06612580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-AAZTA-NI-093
Description: Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-AAZTA-NI-093. Tracer doses of 68Ga-AAZTA-NI-093 will be used to image lesions of prostate cancer by PET/CT.
Study NCT06612749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrative medicine including manual and/or mind-body treatments
Description: Referred HCPs are recommended a multi-modal IM program, include at least one of the following: acupuncture; manual-movement therapies (e.g., acupressure, Anthroposophic medicine touch therapies, reflexology, Qi Gong, and Feldenkrais method); and mind-body medicine (e.g., relaxation and breathing techniques).
Study NCT06613009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI3009
Description: Monoclonal Antibody-Camptothecin Derivative Conjugate for Injection (R \& D code: IBI3009)
Study NCT06613282 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Intensity Transcranial Magnetic Stimulation
Description: * Magnetic stimulation frequency range: 0.1 - 700 Hz.~* Amplitude of the magnetic field at a short distance from the magnetic coil: 1-5 milliTesla.~* Emitter coil dimensions: ⌀28×26 mm.~* Number of emitter coils: 32 coils.~* Covering the entire scalp of a human head with 32 coil emitters.
Study NCT06613282 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auditory and visual stimulation
Description: * Frequency range of light stimulation: 0.1 - 60 Hz.~* Audio stimulation frequency range: 20 - 2000 Hz.~* Sound level: 70 Decibel.~* The wavelength range of visual stimulation: red - 620 - 760 nm; green - 510 - 550 nm; blue - 450 - 480 nm.~* Illuminance: 300 - 350 lx.
Study NCT06612372 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 60-day-6° head-down bed rest
Description: Throughout the bed rest period, subjects carried out all activities of daily living-eating, voiding, recreation, and testing
Study NCT06613178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: acetaminophen
Description: Patient receive IV acetaminophen (and oral placebo) or placebo IV acetaminophen and oral acetaminophen. All drugs are blinded
Study NCT06613178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetaminophen
Description: Patient receive IV acetaminophen (and oral placebo) or placebo IV acetaminophen and oral acetaminophen. All drugs are blinded
Study NCT06611488 — intervention group
Intervention type: OTHER
Intervention: No Intervention: Observational Cohort
Description: No Intervention as the study is bservational Cohort
Study NCT05834127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Group A will receive aerobic exercise in the form of warm up and cool down (both for 5 min)~* Treadmill (30 min) based on Target Heart Rate (calculated using Karvina formula at 60%-70% of heart rate reserve).~* Treatment will be given 3 times a week for 1 month
Study NCT05834127 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga Exercises
Description: Group B will receive yoga movements for 40 min, 3 times a week for 1 month.~* They will be given yoga movements, including 10 min of Kapalbharti Pranayama which includes automatic inhalation with short and forceful exhalations.~* 20 min of yoga movements (Cat-cow pose, Child's pose, Plank pose, Cobra pose - each for 5 min).~* 10 min of meditation/relaxation in Savasana pose
Study NCT04833062 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: In women presenting for a routine antenatal appointment at 20 gestational weeks an ultrasound assessment will be carried out using the 3.5 MHz abdominal probe in order to assess foetal biometry and anatomy as per the guidelines. We will assess the utility of mid- and third trimester ultrasound parameters for prediction of intrapartal events and perinatal outcomes in patients with diabetes mellitus.
Study NCT04833062 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: The maternal baseline characteristics are defined by maternal age at enrollment, parity, number of prenatal visits, some indicators of socioeconomic status and habits, family history of DM (first degree) and prepregnancy hypertension.~The prepregnancy body mass index (BMI; kg/m2) will be calculated using the self-reported prepregnancy maternal weight; the pregnancy weight gain (kg) will be calculated by the difference between final pregnancy weight and prepregnancy maternal weight and was classified according to the prepregnancy BMI.
Study NCT04776577 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Wirecath@ and Abbott PressureWire® (20 patients)
Description: Simultaneous FFR measurements with Wirecath@ and Abbott PressureWire®
Study NCT04776577 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Wirecath® (20 patients)
Description: FFR measurement with Wirecath® only
Study NCT04776577 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Coronary flow reserve
Description: Pressure derived CFR with Wirecath®, Thermodilution CFR with Abbott PressureWire®, Absolut flow CFR with Abbott PressureWire® and Hexacath Rayflow catheter®, Non-invasive echo derived CFR
Study NCT06553482 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FatMAx training intervention
Description: FatMax training program on a treadmill or stationary bicycle, whichever is more convenient for them
Study NCT06553482 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FatMax and physical endurance exercise intervention
Description: FatMax training program on a treadmill or stationary bicycle, whichever is more convenient for them, with muscular endurance exercise
Study NCT06553482 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: No intervention pf physical activity
Study NCT04616612 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SystemCHANGE (TM)
Description: Participants randomized to the refined SystemCHANGE™ intervention will receive 7 personalized sessions with a nurse-interventionist (session 1 virtual face-to-face, sessions 2-7 via phone) and weekly feedback MMS message reports delivered to mobile phones.
Study NCT04616612 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Participants randomized to attention control will receive nurse-led kidney disease self-care education based on materials developed by The National Institute of Diabetes and Digestive and Kidney Diseases and The National Kidney Foundation. Similar to the intervention, participants will receive one virtual visit from the nurse-interventionist and 6 phone calls (weeks 2, 3, 4, 5, 6 and 7) and weekly educational MMS messages delivered by mobile phone.
Study NCT05681832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: The children in this group will participate in a 15-minute HIIT (High-intensity interval training) program twice a week for eight weeks. Motivational interviewing through presentations and Kahoot for the children and their parents will be done at the program's beginning, middle, and end.~The HIIT program will consist of 2.5 minutes of warm-up 12.5 exercises then a cool-down period of 5 minutes. The intensity of the exercise was increased based on each kid's performance and monitored during the sessions using a smartwatch.
Study NCT06570278 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: WGS coupled with MCM
Description: Whole genome will be screened and analysis will focus on pathogenic and likely pathogenic variants. The list of variants of interest will be recorded until examination and discussion during the MCM. MCM will edit a final synthesis concerning the pathogenicity of identified variants.
Study NCT06572111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1839100 (C-14) formulation 1
Description: BI 1839100 (C-14) formulation 1
Study NCT06572111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1839100
Description: BI 1839100
Study NCT06572111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1839100 (C-14) formulation 2
Description: BI 1839100 (C-14) formulation 2
Study NCT06037018 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CC312
Description: Doses from 0.3 to 45 µg/dose by intravenous infusion
Study NCT06296472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: -the experimental group will carry out a program of eccentric exercises following the infiltration and will also wear the wrist brace for 4 weeks.
Study NCT06296472 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: -the standard group will carry out a program of generic exercises following the infiltration and will also wear the wrist brace for 4 weeks.
Study NCT06014879 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Teen Videos
Description: All participants in the Teen Videos will create videos about living well with diabetes, which will be used in the the clinical trial of a new behavioral intervention.
Study NCT06014879 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Type 1 Doing Well (T1DW) Program
Description: Parent and youth will each have access to a version of the app. The study app activities include parents and youth:~* noticing what the youth does well for diabetes;~* setting and tracking a family diabetes goal in the app; and~* having a weekly meeting to review what the youth is doing well with diabetes and progress on the family diabetes goal.~Parents and youth will also have access to age-appropriate libraries of videos with diabetes-specific content.~Parents and youth will also have a conversation with the youth's diabetes care provider at a regularly scheduled diabetes appointment at participating hospital sites.
Study NCT06014879 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diabetes Care Provider Intervention Delivery
Description: Providers will use data-driven youth profiles to discuss youths' diabetes-related strengths and self-management behaviors during a diabetes care visit. This intervention will occur with the parents and youth once in the 6-month period. After each visit, providers will complete a questionnaire.
Study NCT06014879 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes-Related Information and Resources Program
Description: Parent and youth will receive diabetes-related information and resources in the form of electronic handouts. They will receive one handout per month by email during the 6-month intervention period. These handouts include a variety of diabetes-related topics curated by the study team. Handouts will not include any specific information about the youth's health.
Study NCT05394701 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 LipoMicel® soft gels
Description: A maximum single dose of 1260 mg Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)
Study NCT05394701 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RxOmega-3 soft gels (Enteric)
Description: A maximum single dose of 1260 mg Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)
Study NCT05394701 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Complete soft gels (Non-Enteric)
Description: A maximum single dose of 1260 mg Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)
Study NCT06417541 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diseased patients with an indwelling central venous catheter who is referred to autopsy
Description: Photon counting CT is performed and the results are compared to the results of the autopsy
Study NCT04999085 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive care interventions
Description: Subjects will be referred to specialists and/or supportive care interventions based on issues/deficits identified on a baseline geriatric assessment. These interventions will be selected based on deficits or problems identified on baseline assessments. These include referral to physical/occupational therapy for those with physical deficits (Activities of Daily Living impairment, Instrumental Activities of Daily Living impairment, Timed Up and Go, or falls), to optometry/ophthalmology (for visual impairment), to audiology (for hearing impairment), to pharmacist (for polypharmacy), and to cancer center support program (for Mental Health Index 13 criteria).
Study NCT05118217 — intervention group
Intervention type: OTHER
Intervention: This is a non-interventional study
Description: This is a non-interventional study